Skip to main content
Signal8
Launch Terminal

MERIT MEDICAL SYSTEMS INC (MMSI)

Merit Medical Systems, Inc. (MMSI) is engaged in the design, development, manufacturing, and worldwide commercialization of disposable medical products. These devices are crucial for a broad spectrum of diagnostic, therapeutic, and interventional procedures, primarily within the fields of cardiology, radiology, oncology, critical care, and endoscopy. The company operates through two main divisions: Cardiovascular and Endoscopy. Its extensive product portfolio includes advanced solutions for diagnosing and treating conditions in peripheral vessels and organs, as well as a comprehensive suite of cardiac intervention products. The latter encompasses tools for vascular access, angiography, electrophysiology, cardiac rhythm management, fluid and hemodynamic monitoring, hemostasis, and various interventional therapies for heart-related ailments. Additionally, MMSI provides customized procedural solutions, offering critical care items, disinfection protection systems, specialized syringes, manifold kits, and tailored trays and packs. Their offerings further extend to coated tubes and wires, alongside sophisticated sensor components for microelectromechanical systems (MEMS). The company also features pulmonary products, such as laser-cut tracheobronchial stents with their accompanying over-the-wire and direct visualization delivery systems, and dilation balloons used for endoscopic stricture dilation. Gastroenterology products, as well as essential kits and accessories for endoscopy and bronchoscopy procedures, complete their diverse catalog. Merit Medical Systems sells its products to a wide client base, including hospitals and healthcare professionals (physicians, technicians, and nurses) working in alternative care settings. Distribution channels include a direct sales force, authorized distributors, original equipment manufacturer (OEM) partnerships, and custom procedure tray manufacturers, reaching customers throughout the United States and internationally. Founded in 1987, Merit Medical Systems, Inc. has its corporate headquarters situated in South Jordan, Utah.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Instruments & Supplies

Merit Medical Systems, Inc. logo

Merit Medical Systems, Inc.

NASDAQ:MMSIHealthcare
-7.66%$86.24
AH$86.24+0.00%vs close
Mkt Cap$5.17B
Float57.94M
O/S59.92M
Vol
$ Vol
RVOL
Inst Own-
SI6.5%
Earnings
Dilution
Merit Medical Systems, Inc. logoNASDAQ:MMSI$86.24-7.66%
Phase Distribution
29 lead-sponsored trials·8 active·13 completed
Phase 31
Not applicable28
(8 more as collaborator)
Status Overview
Recruiting4
Active, not recruiting4
Completed13
Stopped8

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Terminated

    HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer

    HepaSphere/QuadraSphere Microspheres, PVA, lipiodol, doxorubicin

    Hepatocellular Carcinoma

    Enrollment
    235
    Start
    Jun 2011
    Primary Completion
    Feb 2021
    Completion
    Feb 2021
    NCT01387932
  • Observational
    Completed

    HeRO Vascular Access Device Post Market Procedural Survey Protocol

    -

    End Stage Renal Disease

    Enrollment
    77
    Start
    Dec 2008
    Primary Completion
    Jan 2009
    Completion
    Jan 2009
    NCT00889291
  • Not applicable
    Completed

    HeRO Vascular Access Device Bacteremia Study

    HeRO Vascular Access Device

    Hemodialysis

    Enrollment
    38
    Start
    Mar 2006
    Primary Completion
    Mar 2007
    Completion
    Mar 2007
    NCT00889564
  • Not applicable
    Completed

    Hemodialysis Reliable Outflow (HeRO) Vascular Access Patency Study

    HeRO Vascular Access Device, Conventional ePTFE hemodialysis graft

    Renal Failure Chronic Requiring Hemodialysis

    Enrollment
    72
    Start
    Jul 2004
    Primary Completion
    Mar 2008
    Completion
    Mar 2008
    NCT00890045
  • Observational
    Completed

    HeRO Graft Compared to Permanent Catheters for End Stage Renal Disease (ESRD) Patients Receiving Hemodialysis

    -

    End Stage Renal Disease (ESRD)

    Enrollment
    33
    Start
    Jan 2011
    Primary Completion
    Dec 2013
    Completion
    Dec 2013
    NCT01343251
  • Not applicable
    Terminated

    Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia

    Embosphere Microspheres, TURP

    Benign Prostatic Hyperplasia

    Enrollment
    59
    Start
    Jul 2013
    Primary Completion
    Jun 2017
    Completion
    Dec 2017
    NCT01789840
  • Not applicable
    Completed

    EndoMAXX Endoluminal Valve Technology (EVT) Compared to EndoMAXX

    EndoMAXX Endoluminal Valve Technology (EVT), EndoMAXX

    Malignant Esophageal Strictures

    Enrollment
    60
    Start
    Jan 2015
    Primary Completion
    Oct 2016
    Completion
    Dec 2016
    NCT02159898
  • Observational
    Withdrawn

    Data Collection Registry of the HeRO Graft for End Stage Renal Disease Patients Receiving Hemodialysis

    HeRO Graft implant for dialysis access

    End Stage Renal Failure on Dialysis

    Enrollment
    0
    Start
    Dec 2013est.
    Primary Completion
    Dec 2018est.
    Completion
    Dec 2023est.
    NCT02164175
  • Not applicable
    Terminated

    Evaluation of t-RFA and RF-TVA Prior to/Following Radiation Therapy to Treat Painful Metastatic Vertebral Body Tumor(s)

    STAR™ Tumor Ablation System, StabiliT® Vertebral Augmentation System

    Metastatic Lesions in Vertebral Bodies

    Enrollment
    35
    Start
    Dec 2014
    Primary Completion
    Oct 2016
    Completion
    Oct 2016
    NCT02225223
  • Observational
    Completed

    Post Marketing Surveillance of the CentrosFLO™ Tunneled IJ Catheter

    CentrosFLO Long Term Hemodialysis Catheter

    Pain; Dialysis Catheter

    Enrollment
    10
    Start
    Oct 2013
    Primary Completion
    Jul 2015
    Completion
    Jul 2015
    NCT02349308
  • Observational
    Terminated

    The STAR™ Tumor Ablation Registry

    STAR™ Tumor Ablation System

    Metastatic Lesions in Vertebral Bodies

    Enrollment
    65
    Start
    Oct 2015
    Primary Completion
    Mar 2017
    Completion
    Mar 2017
    NCT02419703
  • Observational
    Completed

    Surfacer System to Facilitate Access in Venous Occlusions

    -

    Chronic Venous Thrombosis, Venous Thrombosis Upper Extremity +1

    Enrollment
    30
    Start
    Feb 2017
    Primary Completion
    Sep 2018
    Completion
    Oct 2018
    NCT02875899
  • Not applicable
    Completed

    Evaluation of the Surfacer System Approach to Central Venous Access

    Central Venous Access Placement

    Venous Occlusion

    Enrollment
    30
    Start
    Dec 2017
    Primary Completion
    May 2019
    Completion
    Jun 2019
    NCT03209050
  • Not applicable
    Active, not recruiting

    C2 CryoBalloon™ 180 Ablation System Dose De-escalation Study.

    C2 CryoBalloon 180° Ablation System

    Barrett Esophagus

    Enrollment
    62
    Start
    Jan 2023
    Primary Completion
    Jun 2026est.
    Completion
    Dec 2026est.
    NCT03311451
  • Observational
    Completed

    Embosphere® PROstate Post Market Study

    Prostate artery embolization

    Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms

    Enrollment
    499
    Start
    Aug 2018
    Primary Completion
    Jan 2020
    Completion
    Jan 2022
    NCT03527589
  • Not applicable
    Completed

    The Merit WRAPSODY™ Endovascular Stent Graft

    WRAPSODY Stent Graft Placement

    Venous Stenosis, Venous Occlusion

    Enrollment
    46
    Start
    Jan 2019
    Primary Completion
    Feb 2020
    Completion
    Jan 2021
    NCT03644017
  • Not applicable
    Withdrawn

    The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease

    Placement of WRAPSODY stent graft

    Stenosis of Artery, Peripheral Arterial Disease +2

    Enrollment
    0
    Start
    Sep 2020est.
    Primary Completion
    Sep 2020est.
    Completion
    Dec 2020est.
    NCT03994185
  • Not applicable
    Completed

    The Merit WRAPSODY AV Access Efficacy Study (WAVE)

    Merit WRAPSODY Endovascular Stent Graft, PTA

    Venous Stenosis, Venous Occlusion

    Enrollment
    357
    Start
    Mar 2021
    Primary Completion
    Feb 2024
    Completion
    Jul 2025
    NCT04540302
  • Not applicable
    Withdrawn

    The Merit WRAPSODY Central Feasibility Study

    Merit WRAPSODY Endovascular Stent Graft

    Venous Stenosis, Venous Occlusion

    Enrollment
    0
    Start
    Mar 2021est.
    Primary Completion
    Jul 2022est.
    Completion
    Feb 2024est.
    NCT04541576
  • Not applicable
    Terminated

    Streamlined Localization Using SCOUT® at Biopsy (STREAMLoc )

    Receives SCOUT at biopsy

    Breast Cancer

    Enrollment
    93
    Start
    Apr 2022
    Primary Completion
    Jan 2024
    Completion
    Jan 2024
    NCT04815291
  • Observational
    Completed

    HepaSphere™ Microspheres Prospective Registry

    HepaSphere Microspheres

    Metastatic Colorectal Cancer

    Enrollment
    105
    Start
    Sep 2016
    Primary Completion
    Jun 2021
    Completion
    Jun 2021
    NCT04866290
  • Observational
    Recruiting

    US Post-Market Surveillance Study of the Surfacer System

    Central Venous Access

    Venous Disease

    Enrollment
    30
    Start
    Feb 2022
    Primary Completion
    Dec 2026est.
    Completion
    Dec 2026est.
    NCT05050799
  • Observational
    Active, not recruiting

    Merit WRAPSODY™ Endoprosthesis for Treatment of Stenosis or Occlusion (WRAP)

    Merit WRAPSODY Endovascular Stent Graft

    Venous Stenosis, Venous Occlusion

    Enrollment
    500
    Start
    Jun 2022
    Primary Completion
    May 2026
    Completion
    Dec 2027est.
    NCT05062291
  • Observational
    Completed

    EmboCube Gelatin Embolization to Control Bleeding or Hemorrhaging

    EmboCube Embolization Gelatin

    Hemorrhage, Bleeding Hemorrhage

    Enrollment
    101
    Start
    Nov 2022
    Primary Completion
    Mar 2024
    Completion
    Apr 2024
    NCT05307783
  • Not applicable
    Active, not recruiting

    GAE Using Embosphere Microspheres vs Corticosteroid Injections for Treatment of Symptomatic Knee OA (MOTION)

    Corticosteroid injection

    Knee Osteoarthritis

    Enrollment
    264
    Start
    Jan 2024
    Primary Completion
    Apr 2026est.
    Completion
    Oct 2027est.
    NCT05818150

1-25 of 29

Search ClinicalTrials.gov for “Merit Medical Systems”